Editorial
Have we considered all barriers to mammalian target of rapamycin inhibition as treatment for diffuse intrinsic pontine glioma?
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a uniformly lethal primary pediatric brain tumor (1,2). Surgical resection is impossible due to its location in the brainstem and invasive nature. Radiotherapy provides just a minor incremental extension in overall survival, whereas chemotherapy is largely ineffective (3-5). There is thus a high unmet need for better therapies.